Aurinia Announces Updated Interim Results from the AURORA 2 Continuation Study of LUPKYNIS (voclosporin) for the Treatment of Lupus Nephritis Nov 1, 2021
Aurinia Pharmaceuticals to Release Third Quarter 2021 Financial Results on November 3, 2021 Oct 27, 2021
Aurinia Pharmaceuticals to Present Five Abstracts at ASN Kidney Week 2021 and ACR Convergence 2021 Oct 26, 2021
Aurinia Pharmaceuticals to Participate in H.C. Wainwright 23rd Annual Global Investment Conference Sep 10, 2021
Aurinia Reports Second Quarter and Six Months 2021 Financial Results and Recent Operational Highlights Aug 5, 2021
